中文 |

Newsroom

NEWS UPDATES
NMPA Conditionally Approves Gumarontinib for Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation

Gumarontinib, an oral highly selective mesenchymal-epithelial transition (MET) inhibitor and a Category 1 innovative new chemical drug, for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation got conditionally approval on March 8, 2023, by the National Medical Products Administration (NMPA) of China.

View More
Research News
View More
Multimedia News
Chinese Light Source Facility Accelerates First Electron Beam

The linear accelerator of China's high-energy synchrotron radiation light source successfully accelerated its first electron beam on Tuesday, its builder has announced. The light source, the High Energy Photon Source (HEPS), is a major science infrastructure project in China built by the Institute of High Energy Physics under the Chinese Academy of Sciences (CAS). The construction started in June 2019 and is expected to take 6.5 years to be completed.

View More
CAS in Media
View More
NEWS ARCHIVE
Contact Us
  • 86-10-68597521 (day)

    86-10-68597289 (night)

  • 86-10-68511095 (day)

    86-10-68512458 (night)

  • cas_en@cas.cn

  • 52 Sanlihe Rd., Xicheng District,

    Beijing, China (100864)

Copyright © 2002 - Chinese Academy of Sciences